Nanoparticle Vaccines

About Opko Health

OPKO Health is a unique, fully-integrated biopharmaceutical and diagnostics company founded in 2007. Its core strategy combines the steady, high-volume revenue of its BioReference Laboratories diagnostics business with targeted therapeutic R&D in multispecific antibodies and long-acting delivery technologies. Key achievements include the global commercialization of NGENLA™ (somatrogon) with Pfizer and the marketing of RAYALDEE® for secondary hyperparathyroidism, while its research subsidiary, ModeX Therapeutics, advances a novel pipeline with partners like Merck and Regeneron. This hybrid model aims to de-risk drug development while pursuing transformative medicines for complex diseases.

About ModeX Therapeutics

ModeX Therapeutics is a private, preclinical-stage biotech focused on creating multispecific biologic drugs using its proprietary MSTAR and Nanoparticle Vaccine platforms. The company, a spin-out/affiliate of OPKO Health, is led by a highly experienced team with deep roots in academia, government (NIH), and industry. Its strategy centers on developing single-molecule therapies that engage multiple disease targets simultaneously, aiming to improve efficacy and overcome limitations of traditional monoclonal antibodies in complex diseases like oncology and virology.

Therapeutic Areas

Other Infectious Diseases Drugs